Over the past several years, numerous transcription factors essential for islet cell development and differentiation have been identified and characterized (reviewed in (1) ).
Several of these transcription factors have also been found to be required for the regulation of β cell function in adults. Furthermore, five of the six genes that contribute to the etiology of Maturity Onset Diabetes of the Young (MODY) encode transcription factors, including Pdx1 (2-4) and NeuroD (5) .
There are many additional transcription factors that are essential for pancreas development, islet cell differentiation, and proper β cell function that have yet to be linked to diabetes in humans including: Ngn3, Pax4, Pax6, Nkx6.1, and Nkx2.2 (6) . These transcription factors each play unique roles in the development of the islet, however very little is known about their functions in the mature β cell.
Nkx2.2 is a homeodomain transcription factor that is essential for the differentiation of islet α and β cells. Nkx2.2 is expressed early in pancreatic progenitors beginning at e9.5 (7) and is ultimately restricted to β cells and a subset of α and PP cells (8) . In Nkx2.2 null mice, β cells and the majority of α cells fail to differentiate and are replaced by ghrelin-producing cells (8; 9) . Expression of Nkx2.2 is maintained in mature β cells in the adult, however since the Nkx2.2 knockout mice die shortly after birth the role of Nkx2.2 in mature β cell function has not been uncovered. Although Nkx2.2 is critical for the specification and differentiation of β cells, the molecular aspects of this function are just beginning to be elucidated. In a previous study, we used an Nkx2.2-derivative approach in transgenic mice to test whether dominant Nkx2.2 activator (Nkx2.2hdVP16) or repressor (Nkx2.2hdEnR) derivatives could substitute for endogenous Nkx2.2 activity in the developing embryonic islet (10; 11) . These studies demonstrated that Nkx2.2 predominantly functions as a transcriptional repressor during endocrine cell differentiation; the Nkx2.2hdEnR derivative is able to rescue the specification of α and β cells during embryogenesis in the absence of endogenous Nkx2.2. We also determined that although the repressor form of Nkx2.2 was able to functionally substitute for endogenous Nkx2.2 in early β cell formation, mature β cells were not fully restored and the Nkx2.2-/-; Nkx2.2hdEnR mice died perinatally.
Based on these findings, we propose that Nkx2.2 functions normally as a repressor during embryonic pancreas development, but may function as an activator in mature β cells. If this hypothesis is correct, a dominant Nkx2.2hdEnR transgene expressed at physiological levels may disrupt endogenous Nkx2.2 function in the adult islet. To test this idea, we maintained the Nkx2.2hdEnR (repressor) transgene on an Nkx2.2 wildtype background and assessed β cell function in the adult islet. This analysis revealed that in postnatal Nkx2.2-repressor mice there is a down regulation of endogenous Nkx2.2 and MafA, two genes that have been proposed to be activated by Nkx2.2 (12; 13). As a consequence of these gene expression changes, the Nkx2.2 transgenic mice exhibit reduced insulin production and impaired glucose-stimulated insulin secretion implicating Nkx2.2 as a critical regulator of β cell function in the adult.
Furthermore, these studies demonstrate that the Nkx2.2-repressor disrupts islet morphology suggesting an additional role for Nkx2.2 in the establishment of normal islet architecture in the mouse.
RESEARCH DESIGN AND METHODS
Mice. Mice were maintained on a Swiss black (Taconic) background and housed in the UCHSC animal resource center. The mice were fed standard rodent chow and all animal procedures were performed according to UCHSC Institutional Review Board approval protocols. Pdx1:Nkx2.2hdEnR, Pdx1:Nkx2.2hdVP16, and Pdx1:Nkx2.2hd control transgenic mice were generated and genotyped as previously described (10) .
Tolerance Tests and Insulin ELISAs.
Mice were fasted 14 hours overnight, weighed, and injected intraperitoneally with 1mg/g glucose per body weight (Sigma 45% solution), 0.75mU/g human insulin (Lilly) or 1mg/g L-arginine (Sigma). Blood glucose concentrations were determined from tail vein blood samples using a Lifescan One Touch glucometer at 0, 15, 30, 60, 90, 120, and 180 minutes postinjection. Samples were collected in heparinized capillary tubes from the tail vein at 0, 5, 15, and 30 minutes post glucose or arginine injection to measure plasma insulin concentrations. To measure total pancreatic insulin content, the pancreas was harvested, protein was extracted with acid-ethanol and measured using the Biorad Protein DC assay. The total pancreatic insulin content was normalized to total protein input. Total pancreatic and plasma insulin levels were measured using the Ultrasensitive rat insulin ELISA kit with the mouse insulin standard (Crystal Chem, Inc.).
Immunohistochemistry.
Whole pancreata was harvested in 1X PBS, fixed overnight in 4% paraformaldehyde for frozen embedding (e18. 5) 
Morphometrics.
Every tenth -5µm section was collected and stained for insulin from three wildtype littermates and three transgenic mice. The total number of islets on each section was counted and total islet area was determined as previously described using ImagePro software (Media Cybernetics) (14) . The area of endocrine cells (α, β, δ, PP) was determined per islet area.
Western blots. Nuclear extracts from pancreatic tissue were prepared as previously described (15) . 100µg total protein per lane was loaded. Antibodies used were mouse anti-Engrailed (DSHB; 1:100) or mouse anti-myc (Sigma; 1:600) and horseradish peroxidase conjugated anti-mouse (Jackson ImmunoResearch; 1:10,000). Blots were developed using chemiluminescence (Pierce).
Quantitative real-time PCR. Total RNA was extracted from whole pancreas or isolated islets from 2-3 month old mice and prepared using a Qiagen RNeasy kit. cDNAs were prepared with oligo(dT) primers and Superscript III (Invitrogen). Real-time PCR was performed using Taqman probes for Nkx2. Results were considered significant when p < 0.05.
RESULTS

Characterization
of adult Pdx1:Nkx2.2hdEnR transgenic mice. We generated transgenic mice expressing the Nkx2.2 repressor derivative (Nkx2.2hd-EnR myc ; 11) under control of the Pdx1 promoter to characterize the molecular function of Nkx2.2 in islet cell specification (10) . We established two stable transgenic lines (7414 and 7660) that accurately express the Nkx2.2hd-EnR myc fusion protein in the islet and can partially rescue embryonic islet cell specification and differentiation in the absence of endogenous Nkx2.2 (10). In the adult islet, Pdx1 is also highly expressed in β cells, allowing us to assess the effect of the Nkx2.2-repressor in the mature β cell.
In the presence of endogenous Nkx2.2, mice derived from both Nkx2.2-repressor lines survive for a normal lifespan, are fertile, and are of comparable weight and size to transgenenegative littermates (hereafter referred to as wildtype littermates). Furthermore, in all assays tested both lines of Nkx2.2-repressor mice display similar phenotypes. In adult pancreata from each transgenic line, a 50kDa fusion protein can be detected by western blot analysis using antibodies directed against either Engrailed or the Myc epitope tag; line 7414 expresses the transgene at higher levels than line 7660 ( Figure 1C and data not shown). To determine the relative expression levels of the Nkx2.2-repressor transgenes compared to endogenous Nkx2.2 in adult mice, we performed quantitative real-time PCR on mRNA extracted from adult pancreas.
The expression level of the Nkx2.2hdEnR transgenic males is significantly lower than endogenous Nkx2.2 levels ( Figure  1E ), suggesting that the transgenes are expressed at levels that should not lead to off-target or non-Nkx2.2 related phenotypes (see below and Discussion).
We generated two additional founder males (7546 and 7566) which give rise to pups that express the transgene, however these pups are growth retarded, appear dehydrated, and do not survive longer than 10 days postnatally. As seen in figure 1, these two males express the Nkx2.2-repressor fusion protein at higher levels than line 7414 and it appears that higher transgene expression might be contributing to the early lethality of the 7546 and 7566 offspring. We have also established two additional transgenic lines (5631 and 5635) that express a Nkx2.2 homeodomain myc tag fusion protein (Pdx1:Nkx2.2hd To determine whether the Nkx2.2-repressor protein had effects on mature β cell function, blood glucose levels were measured in fed Nkx2.2-repressor mice. Prior to weaning, the mice did not exhibit any overt phenotypes. By six weeks of age, male Nkx2.2-repressor transgenic mice exhibited severely elevated blood glucose concentrations compared to wildtype mice; whereas female Nkx2.2-repressor mice, as well as Nkx2.2hd myc control and Nkx2.2-activator mice (10) do not exhibit elevated blood glucose concentrations (Table 1) . Furthermore, the female mice do not become hyperglycemic with age (data not shown). To more accurately assess the degree of pancreatic dysfunction in the Nkx2.2-repressor adult mice, we performed an intraperitoneal glucose tolerance test (IPGTT) in fasted mice aged between 2-3 months. Fasting blood glucose levels were significantly elevated in male transgenic mice at all ages tested (2-6 months; Table 1 ). Upon glucose challenge, male transgenic mice exhibit significantly greater blood glucose concentrations at each time point tested compared to the wildtype controls ( Figure  2A ). The impaired glucose tolerance worsened as the Nkx2.2-repressor transgenic mice aged; blood glucose concentrations peaked at 34 mmol/L at 30 minutes in male transgenic mice aged 5-6 months (data not shown). Female transgenic mice do not have significantly elevated fasting blood glucose levels compared to wildtype female controls, but do show significantly increased glucose levels at 15 minutes post glucose challenge ( Figure 2B ).
Unlike the Nkx2.2-repressor males, the ability to clear glucose does not worsen with age in female mice.
Additionally, neither Nkx2.2hd myc control mice nor Nkx2.2-activator mice demonstrate impaired glucose tolerance (Figure 2A ).
Nkx2.2-repressor transgenic mice have reduced pancreatic insulin content and impaired insulin secretion.
Nkx2.2 has been implicated in direct regulation of insulin transcription (16) . To determine whether the glucose intolerance and diabetic phenotypes observed in the Nkx2.2-repressor transgenic mice were associated with a loss of insulin gene transcription, we assessed insulin mRNA levels in the Nkx2.2-repressor islets using quantitative real-time PCR analysis. These studies demonstrate that insulin mRNA is moderately decreased in Nkx2.2-repressor islets compared to islets from wildtype littermates ( Figure 2D ). In addition, the total pancreatic insulin content was reduced approximately two-fold in Nkx2.2-repressor mice compared to wildtype littermates (Table 2) .
To determine whether the male Nkx2.2-repressor mice also exhibited defects in insulin secretion, we assessed their plasma insulin levels in response to IPGTT. The Nkx2.2-repressor transgenic mice were unable to mount an insulin secretory response upon glucose challenge. ( Figure  2C ). Female Nkx2.2-repressor mice also had impaired insulin secretion in response to glucose stimuli (data not shown).
To determine whether the failure of Nkx2.2 male repressor mice to secrete insulin was due to impaired insulin release, we tested the Nkx2.2-repressor mice responsiveness to arginine, a secretogogue that promotes insulin secretion via mechanisms independent of glucose metabolism (17) . Upon arginine stimulation male transgenic animals have impaired glucose clearance and significantly reduced insulin secretion compared to wildtype littermate controls ( Figure 2E-F) . These results suggest that the β cells of the Nkx2.2-repressor mice appear to have multiple defects in the insulin secretion pathway.
Nkx2.2-repressor transgenic mice are not insulin resistant.
Although peripheral insulin resistance would not be expected in the Nkx2.2-repressor mice since the Nkx2.2hdEnR transgene is expressed specifically in β cells, we wanted to eliminate the possibility that insulin resistance was contributing to the observed glucose intolerance.
We examined insulin sensitivity directly by measuring blood glucose levels of the diabetic Nkx2.2-repressor male and female mice in response to an insulin challenge. Although the fasting blood glucose concentrations begin and end much higher for the male transgenic animals, the rate of glucose disposal in male and female Nkx2.2-repressor mice is very similar to wildtype mice (Figure 3 (18) (19) (20) are not significantly altered, as assessed by real-time PCR (Figure 4) .
Functional β cells fail to form in the Nkx2.2-repressor transgenic mice
Expression of the Nkx2.2-repressor transgene results in the disruption of normal β cell function in the adult. This phenotype is in marked contrast to that observed in the Nkx2.2 null mice, where α and β cells fail to differentiate appropriately and the mice die at birth, suggesting that we have not merely created a dominant negative Nkx2.2 protein. This is also consistent with our previous studies, which provide evidence that Nkx2.2 normally functions as a repressor during islet cell specification, but Nkx2.2 activator functions may be required to allow β cell maturation and function (10) . These findings would suggest that expression of the Nkx2.2-repressor in the presence of endogenous Nkx2.2 would not disrupt islet cell specification in the embryo, but may cause later β cell differentiation defects. To determine when and how the Nkx2.2-repressor might be affecting pancreatic formation and function we performed histological analysis to assess exocrine and endocrine cell formation in the Nkx2.2-repressor transgenic mice. We do not observe a difference in the size or weight of the whole pancreatic organ and mRNA and protein levels of the exocrine enzyme amylase are unchanged (data not shown). As shown in Figure 5 , overall islet morphology, size, and number in the Nkx2.2-repressor transgenics are also indistinguishable from the wildtype littermates and the Nkx2.2hd myc controls. Standard morphometric analysis of adult islets also indicated there was no change in total islet cell mass of the transgenic animals (data not shown). To determine the status of the individual islet cell subpopulations, we performed immunofluorescence to quantify the respective islet cell populations. Unlike the Nkx2.2 null mice, morphometric analysis of the individual endocrine cell types indicated that each of the islet cell populations was present in their expected relative ratios (Figure 5F and G; data not shown).
Furthermore, there was no significant difference in the number of β cells or the other endocrine cell types in Nkx2.2-repressor mice ( Figure 5 and data not shown). We further assessed the differentiation state of β cells by looking at four β cell markers: Pdx1, MafA, Gck, and Glut2. Pdx1 is coexpressed with all insulin-positive cells and Pdx1 mRNA expression is unchanged (Figure 4, 6B) . However, consistent with the observed decrease in MafA mRNA expression, the number of insulin-positive cells that coexpress MafA is significantly reduced ( Figure 6E ). Additionally, Glut2 mRNA, but not Gck mRNA, is down regulated in the adult islet (Figure 4 ). Glut2 protein expression is also significantly reduced in neonatal and adult islets (6G -6J). This indicates that the Nkx2.2-repressor transgene does not interfere with islet cell specification during pancreogenesis, but does disrupt the activation of genes such as MafA and Glut2 that are required for terminal β cell differentiation and/or β cell function. These results are consistent with our previous finding that Nkx2.2 normally functions as a repressor during islet cell differentiation, but may function predominantly as an activator during β cell maturation and maintenance.
Islet architecture is disrupted in Nkx2.2-repressor transgenic mice. Surprisingly, despite the fact that the individual islet subtypes were present in their normal numbers and ratios, the α, δ, and PP cells were mislocalized from the periphery of the islet and scattered throughout the islet core in both male and female Nkx2.2-repressor mice ( Figure 5B -C, 5F -G and data not shown). Islets of adult wildtype littermates and control transgenic mice (Nkx2.2hd myc ) have normal islet architecture ( Figure 5B-D, I and J).
To determine whether the disruption of islet architecture was initiated at the onset of islet formation, we examined islet structure in perinatal mice. Even at the earliest time point of islet assembly, the Nkx2.2-repressor mice fail to form characteristic islet organization ( Figure 5H) .
Additionally, we often observe abnormal clustering of glucagonpositive cells in the perinatal transgenic animals ( Figure 5H, arrowheads) . This abnormal islet architecture is similar to that observed in the adult MafA null mice, suggesting that the reduction of MafA may be contributing to this phenotype. However, a disruption of islet organization is not observed in the neotnatal MafA null mice, indicating that the Nkx2.2-repressor interferes with organization of islet architecture through additional regulatory pathways.
DISCUSSION
The data presented in this study suggest a critical role for Nkx2.2 in maintaining mature β cell function and forming correct islet architecture. Consistent with our previous findings that Nkx2.2 functions as a repressor during embryonic islet cell specification (10), embryonic pancreas development and differentiation proceeds normally in the Nkx2.2-repressor mice until birth, when the Nkx2.2-repressor derivative interferes with the expression and function of endogenous Nkx2.2, leading to a reduction MafA, Glut2 and insulin gene expression in mature β cells. Furthermore, the islets of the Nkx2.2-repressor mice fail to cluster properly and disrupted islet architecture persists throughout adulthood.
In the adult Nkx2.2-repressor mice, β cells display impaired insulin secretion, suggesting that Nkx2.2 is also an important regulator of mature β cell function. We are currently exploring whether the defects observed in the perinatal islets contribute to the functional defects that are manifest later in the adult β cell.
In this analysis we utilized a dominant repressor derivative of Nkx2.2 to assess the function of Nkx2.2 in the mature islet. While there are limitations associated with this approach and the transgene does not contain regions of the Nkx2.2 protein that may contribute to the specificity of DNA binding, we have been able to demonstrate that the Nkx2.2hdEnR transgene is able to functionally substitute for endogenous Nkx2.2 in the embryo (10) . Furthermore, we have determined that the observed adult β cell phenotypes are not caused by inordinately high levels of transgene expression that could lead to transcriptional squelching effects or misregulation of gene targets of the closely related pancreatic transcription factor Nkx6.1; however, we cannot definitively rule out that other nonspecific off-target binding of the transgene is occurring. Finally, we have shown that the Nkx2.2-repressor is able to interfere with the expression of two known endogenous Nkx2.2 targets, Nkx2.2 itself and MafA, suggesting that the dominant transgene is functioning to block endogenous Nkx2.2 activity in the adult islet. It is possible that this reduction of Nkx2.2 in the islet is a major contributing factor to the disruption of normal β cell function.
We observed two β cell defects related to the expression of the Nkx2.2-repressor: a reduction of insulin content and a defect in insulin secretion. Insulin mRNA levels are moderately reduced, and insulin protein content is decreased in the adult islet of Nkx2.2-repressor mice approximately 2-3 fold. These findings are consistent with previous in vitro studies, which suggest that Nkx2.2 regulates insulin transcription directly (16) ; however, we also observe a reduction of MafA, which could contribute to the decrease in insulin gene expression. We do not detect changes in other known regulators of insulin transcription including Pdx1, NeuroD, and Islet1 (Figure 4) , suggesting that the defect is primarily associated with transcriptional targets of Nkx2.2. Interestingly the decrease of circulating insulin upon glucose challenge in the Nkx2.2-repressor males is much more severe than was expected from the moderate reduction of islet insulin content; therefore there may be additional defects associated with the insulin secretion pathway.
The decreased expression of Glut2 likely contributes to the insulin secretion defects.
Our discovery that the Nkx2.2hdEnR transgene does not disrupt embryonic pancreas development, but does interfere with adult β cell functions strengthens our hypothesis that Nkx2.2 functions normally as a repressor during embryonic development but as an activator in the mature β cell. This is consistent with our previous findings that the Nkx2 A novel finding of this study is that the Nkx2.2-repressor mice display altered islet morphology and this defect is manifest at the onset of islet formation. We have been unable to identify the underlying cause of the altered islet architecture; islet cell ratios are normal and there are no significant alterations in expression of many of the islet cell adhesion molecules, including the integrins (β1, α3, α 5 or α 6), cadherins 1 and 2, Ncam, α and β catenins, occludin or members of MMP family (data not shown). Of note, islet architecture is also disrupted in several other transcription factor mutation models, including MafA, and in each case the contributing cause of this phenotype has yet to be ascertained (4; 21-23) . At this point, we cannot distinguish whether the defects in β cell function are due directly to inappropriate Nkx2.2-repressor activity or are a consequence of the disrupted islet architecture.
We have demonstrated that Nkx2.2 functions in the mature islet to influence the formation of the characteristic islet architecture and to maintain normal β cell functions, including optimal expression of the insulin genes and glucose-stimulated insulin secretion. Interestingly, the β cell defects observed in the Nkx2.2-repressor transgenic mice are similar to defects associated with several MODY transcription factors. Additional studies with hypomorphic and conditional Nkx2.2 alleles are ongoing to determine the mechanism by which Nkx2.2 may contribute to β cell dysfunction. Real-time PCR for select islet genes was performed using total RNA from isolated islets of wildtype (black) and Nkx2.2-repressor (gray) mice (n = 4 each; Islets were pooled from two mice for each sample). Nkx2.2, MafA, and Glut2 are significantly decreased in Nkx2.2-repressor islets. * p < 0.005. All other genes are not significantly changed. Error bars represent s.e.m. of four individual samples for each genotype. 
